Welcome to our dedicated page for INSMED SEC filings (Ticker: INSM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Insmed Incorporated filings document formal disclosures for its commercial biopharmaceutical portfolio and respiratory and inflammatory pipeline. Recent Form 8-K reports furnish financial results, investor presentations, Regulation FD materials, clinical-study updates for ARIKAYCE and brensocatib, regulatory approval announcements for BRINSUPRI, and portfolio additions such as INS1148.
The company’s proxy materials describe board elections, executive compensation, equity awards, shareholder voting matters and governance practices. Other current reports document compensatory arrangements, director-transition disclosures, exhibits and Inline XBRL cover-page data tied to Insmed’s Nasdaq-listed common stock.
Insmed Incorporated reported results from its annual shareholder meeting held on May 13, 2026. Shareholders elected Elizabeth McKee Anderson and Clarissa Desjardins, Ph.D., as Class II directors to serve until the 2029 annual meeting. Anderson received 153,734,471 votes for and 32,130,980 withheld, while Desjardins received 164,437,828 votes for and 21,427,623 withheld; each had 11,564,082 broker non-votes.
Shareholders also approved, on an advisory and non-binding basis, the 2025 compensation of the company’s named executive officers, with 162,133,728 votes for, 23,657,325 against, 74,398 abstentions and 11,564,082 broker non-votes. In addition, shareholders ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the year ending December 31, 2026, by 190,386,612 votes for, 6,997,613 against and 45,308 abstentions.
INSM filed a Form 144 notice of proposed sale of Common Stock by an affiliate. The filing lists two proposed sale dates: 05/11/2026 and 05/13/2026, showing proposed sale quantities of 12,949 shares and 7,854 shares, respectively. The record lists Martina Flammer as the selling person and shows holdings figures of 1,300,105 and 897,137 adjacent to those entries. The securities are Common Stock noted for trading on NASDAQ.
INSM files a Form 144 reporting a proposed sale of common stock. The filing lists a reported sale of 88,060 shares by Roger Adsett on 04/01/2026. The notice also records a Stock Plan Activity entry dated 05/11/2026 under issuer treatment.
INSM submitted a Form 144 notice reporting proposed sales of Common Stock by an insider. The filing lists prior sales during the past three months by Michael Smith: 19,638 shares on 03/30/2026 and 24,774 shares on 02/24/2026. The filing references Stock Plan Activity and shows post-transaction holdings of 2,964,929 and 3,859,153 shares respectively.
INSM submitted a Form 144 notice listing 7,854 shares of Common Stock to be sold on 05/11/2026 under stock plan activity. The filing also records that Martina Flammer sold 12,949 shares on 05/11/2026.
INSM reports proposed sales of Common Stock by William Lewis under Rule 144. The filing lists multiple proposed sale dates with 10,699 shares on each listed trade date, including 05/04/2026, 04/16/2026, 04/06/2026, 03/19/2026, 03/05/2026, and 02/19/2026.
The Securities Information section shows 216,752,451 with an associated date of 05/13/2026, and the filing references Stock Plan Activity on 05/11/2026. The filing names William Lewis as the selling party and provides addresses for notification.
Insmed Inc.'s Chief Medical Officer, Martina Flammer, M.D., reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire 12,949 shares of common stock at $17.07 per share, then sold 12,949 shares in open-market transactions at weighted average prices of $100.35 for 12,119 shares and $101.18 for 830 shares. The sales were made pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025. Following these transactions, she holds 83,243 shares of Insmed common stock directly.
Insmed reported strong first-quarter 2026 growth, with total revenues of $306.0 million, up from $92.8 million a year earlier, driven by the U.S. launch of BRINSUPRI and continued ARIKAYCE demand. BRINSUPRI generated $207.9 million, while ARIKAYCE contributed $98.1 million and remained in growth eight years post-launch.
The company still posted a net loss of $163.6 million, though this narrowed from $256.6 million in 2025 as operating leverage improved. Management reiterated 2026 revenue guidance of at least $1 billion for BRINSUPRI and $450–$470 million for ARIKAYCE, and highlighted a goal of reaching cash-flow positivity in 2027 supported by roughly $1.2 billion in cash and marketable securities.